Mankind Pharma Limited (NSE:MANKIND) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Aug 03
MANKIND Share Price Performance
₹2,550.60
77.45 (3.13%)
22.7% undervalued intrinsic discount
₹3,300.00
Fair Value
Price ₹2,550.60
AnalystHighTarget ₹3,300.00
AnalystConsensusTarget ₹2,787.90
AnalystLowTarget ₹2,150.00
Fair Value₹3,300.00
Share Price₹2,550.60
22.7% undervalued intrinsic discount
MANKIND Community Narratives
AN
Fair Value ₹3.30k 22.7% undervalued intrinsic discount
India's Rising Middle Class And Urbanization Will Reshape Healthcare Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹2.80k 8.9% undervalued intrinsic discount
Chronic Therapy Demand And E-Commerce Will Fuel Future Expansion
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value ₹2.15k 18.6% overvalued intrinsic discount
Rising Regulatory Hurdles And Pricing Restrictions Will Undermine Future Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
MANKIND Community Fair Values
- ₹3.30kFV22.7% undervalued intrinsic discount16.55%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrativeabout 18 hours ago author updated this narrative
Recent MANKIND News & Updates
We Think You Should Be Aware Of Some Concerning Factors In Mankind Pharma's (NSE:MANKIND) Earnings
Jul 23Mankind Pharma (NSE:MANKIND) Has A Pretty Healthy Balance Sheet
Jun 28The Mankind Pharma Limited (NSE:MANKIND) Full-Year Results Are Out And Analysts Have Published New Forecasts
May 24Here's Why Mankind Pharma (NSE:MANKIND) Has Caught The Eye Of Investors
May 11Mankind Pharma Limited's (NSE:MANKIND) Share Price Not Quite Adding Up
Mar 02Mankind Pharma Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 45.86
- Gross Margin
- 69.76%
- Net Profit Margin
- 14.66%
- Debt/Equity Ratio
- 58.4%
Mankind Pharma Limited Competitors
Snowflake Analysis
About MANKIND
- Founded
- 1991
- Employees
- 26978
- CEO
- WebsiteView website
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
Market Insight
Why today’s lofty prices test investors, and how to stay invested without losing your edge.
Continue reading
Indian Market Performance
- 7 Days: 1.4%
- 3 Months: -1.3%
- 1 Year: -7.2%
- Year to Date: -0.9%
Over the last 7 days, the market has risen 1.4%, driven by gains of 2.9% in the Consumer Discretionary sector. In contrast, the market has seen a decline of 7.2% over the last 12 months. Looking forward, earnings are forecast to grow by 16% annually. Market details ›